Adbry/Adtralza Market Report 2026

Adbry/Adtralza Market Overview

• The Adbry/Adtralza market growth in the historic period has been driven by limitations of topical corticosteroids, rising prevalence of atopic dermatitis • Market expansion is supported by growing eczema patient population, expansion into pediatric use • Growth Driver: Rising Atopic Dermatitis Prevalence Fuels Growth of Adbry/Adtralza Market • Market Trend: Advancements In Biologic Treatments For Atopic Dermatitis With Leo Pharma's Expansion Of Adbry (Tralokinumab-ldrm) Approval • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Adbry/Adtralza Market?

Adbry (also known as adtralza) is a monoclonal antibody medication used to treat moderate to severe eczema (atopic dermatitis) in adults and children aged 6 years and older. It works by inhibiting interleukin-13 (IL-13), a protein involved in the inflammatory process of eczema. By targeting IL-13, Adbry/Adtralza helps reduce skin inflammation, itching, and rashes. The main indication for adbry/adtralza are atopic dermatitis, other dermatological conditions. Atopic dermatitis (AD) is a chronic skin condition characterized by itchy, inflamed skin that can lead to significant discomfort and impact daily life. These are distributed through various distribution channels such as hospital and clinics, retail and specialty pharmacies and are used by various end users such as adult patients, geriatric patients.

What Is The Adbry/Adtralza Market Growth Forecast?

The growth in the forecast period can be attributed to growing eczema patient population, expansion into pediatric use, increasing biologic therapy awareness, improved reimbursement coverage, continued innovation in dermatology biologics. Major trends in the forecast period include rising adoption of targeted dermatology biologics, growing use in moderate to severe atopic dermatitis, expansion of il 13 targeted therapies, increasing long term maintenance biologic therapy, higher patient demand for steroid sparing treatments.

Global Adbry/Adtralza Market Segmentation

1) By Indication: Atopic Dermatitis, Other Dermatological Conditions, 2) By Distribution Channel: Hospital and Clinics, Retail and Specialty Pharmacies 3) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Adbry/Adtralza Market?

The rising prevalence of atopic dermatitis is expected to propel the growth of the adbry/adtralza market going forward. Atopic dermatitis, commonly known as eczema, refers to a chronic inflammatory skin condition characterized by intense itching, redness, and irritation. The rising prevalence of atopic dermatitis is due to factors such as increased air pollution, urban living conditions, changes in childhood skin care practices, and genetic predispositions. Adbry/adtralza, a monoclonal antibody targeting the interleukin-13 (IL-13) pathway, helps atopic dermatitis by reducing inflammation and immune system overactivity, thereby alleviating symptoms such as itching, redness, and skin irritation in patients with moderate-to-severe forms of the condition. For instance, in December 2023, according to the National Library of Medicine (NLM), a US-based biomedical library, the global prevalence of atopic dermatitis is estimated at 2.6%, affecting approximately 204.05 million people worldwide, with about 101.27 million adults and 102.78 million children diagnosed with the condition. Therefore, the rising prevalence of atopic dermatitis is driving the adbry/adtralza industry. The rising healthcare expenditure is expected to propel the growth of adbry/adtralza market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Healthcare expenditure refers to the total amount of money spent on healthcare services and products within a specific period. Healthcare expenditure plays a crucial role in supporting the availability and accessibility of innovative treatments such as Adbry (also known as adtralza), as increased spending on healthcare systems enables the coverage and distribution of advanced biologics for the management of conditions such as moderate-to-severe atopic dermatitis, improving patient outcomes while also facilitating broader access to these essential therapies. For instance, in May 2024, according to a report published by Office For National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rising healthcare expenditure is driving the growth of adbry/adtralza industry.

Key Players In The Global Adbry/Adtralza Market

Major companies operating in the adbry/adtralza market are LEO Pharma Inc.

Global Adbry/Adtralza Market Trends and Insights

Major companies operating in the adbry/adtralza market are focusing on developing approved drugs such as biologic treatment specifically designed to inhibit interleukin-13 (IL-13) to gain improved therapeutic outcomes for patients with atopic dermatitis. Biologic treatment refers to a type of therapy that uses biologically derived substances, such as monoclonal antibodies, proteins, or vaccines, to target specific components of the immune system or cellular processes involved in diseases, offering a more targeted and often more effective approach for conditions like autoimmune disorders, cancer, and chronic inflammatory diseases. For instance, in December 2023, Leo Pharma, a Denmark-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of Adbry (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD). This marks Adbry as the first and only biologic specifically designed to inhibit interleukin-13 (IL-13), a key cytokine involved in the inflammatory processes of atopic dermatitis.

Regional Insights

North America was the largest region in the adbry/adtralza market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Adbry/Adtralza Market?

The adbry/adtralza market consists of sales of adbry (Tralokinumab-ldrm), adtralza (Tralokinumab), delgocitinib, TMB-001, and fucidin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adbry/Adtralza Market Report 2026?

The adbry/adtralza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adbry/adtralza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.